Dan O'Day, Gilead CEO (Alex Brandon, AP Images)
Covid-19 roundup: In fifth open letter, Daniel O’Day touts inhalant remdesivir, promises 2M doses by year's end; Merck’s antiviral moves into PhII
Since remdesivir began capturing treatment hopes early in the outbreak, one clear factor has limited its potential: Antivirals are known to work best in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.